SCHEMBL2134193

SCHEMBL2134193

CC(NC(=O)c1ccc(C(C)(C)C)cc1)c1ccc(OCc2ccccc2)cn1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CACNA1I Q9P0X4 1/20 0.58
NR4A2 P43354 2/20 0.52
RXRA P19793 1/20 0.52
RXRB P28702 1/20 0.52
GRM5 P41594 1/20 0.47
NR1H4 Q96RI1 1/20 0.46
GPR132 Q9UNW8 1/20 0.46
NR4A1 P22736 1/20 0.46
NR4A3 Q92570 1/20 0.46
HDAC3 O15379 1/20 0.46
HDAC1 Q13547 1/20 0.46
HDAC2 Q92769 1/20 0.46
NCOR2 Q9Y618 1/20 0.46
ALDH1A1 P00352 1/20 0.46
LMNA P02545 1/20 0.45
RAB9A P51151 1/20 0.45
P4HTM Q9NXG6 1/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
KMT2A Q03164 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2134187 1.00 CACNA1I (0.58) CACNA1INR4A2RXRARXRBGRM5
SCHEMBL2140009 0.87 CACNA1I (0.53) CACNA1IGPR132ALDH1A1LMNAMEN1
SCHEMBL2140013 0.87 CACNA1I (0.53) CACNA1IGPR132ALDH1A1LMNAMEN1
SCHEMBL2134729 0.83 CACNA1I (0.73) CACNA1INR1H4ALDH1A1LMNARAB9A
SCHEMBL2134726 0.83 CACNA1I (0.73) CACNA1INR1H4ALDH1A1LMNARAB9A
SCHEMBL2136815 0.83 CACNA1I (0.60) CACNA1INR1H4RAB9ANPC1
SCHEMBL2139813 0.83 CACNA1I (0.60) CACNA1INR1H4RAB9ANPC1
SCHEMBL2136809 0.83 CACNA1I (0.60) CACNA1INR1H4RAB9ANPC1
SCHEMBL2139621 0.83 CACNA1I (0.51) CACNA1INR4A2RXRARXRBP4HTM
SCHEMBL21823859 0.83 CACNA1I (0.51) CACNA1INR4A2RXRARXRBP4HTM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3632899-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RaQualia Pharma Inc. (JP) 2020-04-08 EP disclosed
EP-2435407-B1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2019-12-25 EP disclosed
US-9522140-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2016-12-20 US disclosed
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC (JP) 2015-11-12 US disclosed
US-9101616-B2 Aryl substituted carboxamide derivatives as calcium or sodium channel blockers RAQUALIA PHARMA INC. (JP) 2015-08-11 US disclosed
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2012-04-26 US disclosed
WO-2010137351-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS RAQUALIA PHARMA INC. (JP) 2010-12-02 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120101105-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H CACNA1I 1/4885NR4A2 2333/4885RXRA 4034/4885
US-20150322052-A1 ARYL SUBSTITUTED CARBOXAMIDE DERIVATIVES AS CALCIUM OR SODIUM CHANNEL BLOCKERS CACNA1I, CACNA1G, CACNA1H CACNA1I 1/4885NR4A2 2318/4885RXRA 4012/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.